Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6314124 | 0.99 | MAPT (0.42) | MAPTTP53KEAP1NFE2L2MEN1 | |
| SCHEMBL4458341 | 0.87 | CNR1 (0.42) | MAPTTP53KEAP1NFE2L2MEN1 | |
| Hydrochloric Acid SCHEMBL6314832 | 0.86 | SMN1; SMN2 (0.42) | MAPTTP53KEAP1NFE2L2MEN1 | |
| SCHEMBL4453856 | 0.85 | SLC9A1 (0.41) | MAPTTP53KEAP1NFE2L2MEN1 | |
| Hydrochloric Acid SCHEMBL6314063 | 0.84 | SLC9A1 (0.40) | TP53KEAP1NFE2L2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6314820 | 0.84 | CNR1 (0.41) | TP53KEAP1NFE2L2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6313195 | 0.83 | SLC9A1 (0.39) | TP53KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL4454362 | 0.83 | MEN1 (0.39) | TP53KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL4454500 | 0.83 | SLC9A1 (0.56) | MAPTTP53KEAP1NFE2L2MEN1 | |
| Hydrochloric Acid SCHEMBL6315706 | 0.83 | MEN1 (0.38) | TP53KEAP1NFE2L2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | PFIZER INC. | 2003-11-13 | — | — | US | claimed |
| US-20030212072-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2003-11-13 | — | — | US | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | claimed |
| WO-2015189236-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-12-17 | — | — | WO | disclosed |
| CN-1351497-A | Aminopyrimidines as sorbitol dehydrogenase inhibitors | PFIZER PROD INC (US) | 2002-05-29 | — | — | CN | disclosed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | MAPT 4820/4885TP53 4547/4885KEAP1 1932/4885 |
| US-20010056095-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | MAPT 256/4885TP53 4691/4885KEAP1 2193/4885 |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | NHERF1, SLC5A1, SLC5A2 | MAPT 3477/4885TP53 4751/4885KEAP1 166/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | MAPT 4649/4885TP53 4700/4885KEAP1 2075/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | MAPT 2399/4885TP53 4847/4885KEAP1 173/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | MAPT 4418/4885TP53 4706/4885KEAP1 313/4885 |
| US-20030212072-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | MAPT 256/4885TP53 4691/4885KEAP1 2193/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | MAPT 2399/4885TP53 4847/4885KEAP1 173/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | MAPT 4477/4885TP53 4575/4885KEAP1 2315/4885 |
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | MAPT 3856/4885TP53 3427/4885KEAP1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.